Literature DB >> 29411927

Oral contraception in adolescents with type 1 diabetes and its association with cardiovascular risk factors. A multicenter DPV study on 24 011 patients from Germany, Austria or Luxembourg.

Barbara Bohn1,2, Kirsten Mönkemöller3, Dörte Hilgard4, Axel Dost5, Karl Otfried Schwab6, Eggert Lilienthal7, Elke Hammer8, Kathrin Hake9, Maria Fritsch10, Bettina Gohlke11, Carine de Beaufort12,13, Reinhard W Holl1,2.   

Abstract

OBJECTIVE: To investigate differences in cardiovascular risk factors and metabolic control in girls with type 1 diabetes with or without use of oral contraceptives (OC) from the multicenter "diabetes prospective follow-up" (DPV) registry.
METHODS: Twenty-four thousand eleven adolescent girls (13 to < 18 years of age) from Germany, Austria or Luxembourg with type 1 diabetes from the DPV registry were included in this cross-sectional study. Multivariable regression models were applied to compare clinical characteristics (hemoglobin A1c [HbA1C ], blood pressure, serum lipids, body mass index) and lifestyle factors (smoking, physical inactivity, alcohol consumption) between girls with or without OC use. Confounders: age, diabetes duration and migration background. STATISTICAL ANALYSIS: SAS 9.4.
RESULTS: In girls with type 1 diabetes and OC use, clinical characteristics and lifestyle factors were less favorable compared to non-users. Differences were most pronounced for the prevalence of dyslipidemia (OC-users: 40.0% vs non-users: 29.4; P < .0001) and the number of smokers (OC-users: 25.9% vs non-users: 12.5%; P < .0001). OC use, sociodemographic characteristics and lifestyle factors explained between 1 and 7% of the population variance in serum lipids and blood pressure. The use of OC explained a small additional proportion in all variables considered (<1%).
CONCLUSIONS: OC use in adolescent girls with type 1 diabetes was associated with a poorer cardiovascular risk profile. Biological risk factors were partly explained by a clustering of sociodemographic and lifestyle factors with a small additional contribution of OC use. Prescription of OC should therefore be combined with a screening for cardiovascular risk factors and targeted education.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescent health; cardiovascular risk; lifestyle; oral contraception; type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29411927     DOI: 10.1111/pedi.12656

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  2 in total

Review 1.  Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative.

Authors:  Maria de Fátima Brito; Carla Torre; Beatriz Silva-Lima
Journal:  Front Med (Lausanne)       Date:  2021-07-06

2.  Sexual Risk Behaviors of Adolescents with Type 1 Diabetes in Comparison with Their Peers.

Authors:  Betina Kandyla; Artemis Tsitsika; Alexandra Soldatou; Chara Tzavara; Spyridon Karanasios; Kyriaki Karavanaki
Journal:  Children (Basel)       Date:  2021-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.